NEW YORK (GenomeWeb News) – Pathway Genomics, a new direct-to-consumer genetic testing firm, launched today, offering genotyping and analysis for disease risk and heredity for under $250.
The San Diego, Calif.-based company said that its on-site lab has been certified by California regulators and has received CLIA clearance. The company said its testing enables customers to learn about disease risk, adverse drug responses, carrier status, and ancestral history.
Pathway Genomics joins a nascent field of DTC genomics providers, pioneered by 23andMe, Navigenics, and Decode Genetics among others.
The private company received its principal start-up funding from The Founders Fund, Edelson Technology Partners, and Western Technology Investment.
Pathway Genomics was founded by CEO Jim Plante, who has founded four other technology companies in the wireless, automotive, consumer products, and risk-management fields. The company's scientific team is led by CSO David Becker, who has worked in Alzheimer's research at Torrey Pines Therapeutics.
"Evaluating an individual's genetic profile is important, but it only reveals part of a person's health and wellness. The overall picture should also include information about a person's family history and lifestyle," Becker said in a statement.
Pathway Genomics is offering its testing service through its website.